The Urology Center of Colorado

Recent papers from The Urology Center of Colorado

1. ID #1021 Secondary analysis of outcome by treatment and age in ependymoma: A Report from the Children’s Oncology GroupNeuro-Oncology Pediatrics · 2026
2. Physician Insights on Transitioning Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy From Intravenous Immunoglobulin to Subcutaneous Efgartigimod PH20 (P7-9.016)Neurology · 2026
3. Real-world clinical outcomes of patients with localized prostate cancer treated with radical prostatectomy in SEER-MedicareJournal of Comparative Effectiveness Research · 2026
4. Prevalence and role of psychiatric conditions in patients diagnosed with anterior knee painJournal of Orthopaedic Reports · 2026
5. Local Drug Delivery Systems for Cancer TherapyACS Applied Materials & Interfaces · 2025
6. Sustaining neuromuscular activation after total knee arthroplasty preserves skeletal muscle fiber size, contractility, and innervation in older adultsExperimental Gerontology · 2025
7. Prevalence and treatment patterns of erectile dysfunction and hypogonadism in men with spina bifida: a retrospective studyFrontiers in Urology · 2025
8. Genetic ancestry concordant RNA splicing in prostate cancer involves oncogenic genes and associates with recurrencenpj Precision Oncology · 2025
9. North American study and meta-analysis evaluating performance of Bladder EpiCheck ® , a FDA cleared test, in non-muscle invasive bladder cancer recurrenceBladder Cancer · 2024
10. Testicular mapping-guided sperm retrieval vs. upfront microTESE in non-obstructive azoospermia: a comparison of sperm retrieval, pregnancy and live-birth ratesTranslational Andrology and Urology · 2024
11. Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)Prostate Cancer and Prostatic Diseases · 2024
12. Instability and the Anatomic Total Shoulder ArthroplastyJournal of the American Academy of Orthopaedic Surgeons · 2024
13. Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studiesFuture Oncology · 2024
14. Rapid and deep prostate-specific antigen (PSA) response to apalutamide plus ADT and survival in metastatic castration-sensitive prostate cancer (mCSPC) in real world practice in the US (OASIS Project).Journal of Clinical Oncology · 2024
15. Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).Journal of Clinical Oncology · 2024
16. Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: a subgroup analysis of the randomised clinical TITAN studyCancer Urology · 2024
17. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 TrialThe Journal of Urology · 2024
18. Differences in real‐world outcomes by risk classification for localized prostate cancer patients after radiation therapyThe Prostate · 2024
19. Abstract CT018: TMPRSS2-ERG and RB1 as candidate predictive biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)Cancer Research · 2024
20. Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk StratificationThe Journal of Urology · 2023